PeptideClinicLocatorOverview
MOTS-c is a mitochondrial-derived peptide that has attracted interest for metabolic regulation, exercise mimetic effects, and insulin sensitivity. Research is still early, with primarily animal studies. In the US, MOTS-c is prohibited for compounding—Category 2 with no approved pathway. It is not FDA-approved for any use. People may encounter it in research or overseas contexts, but it is not a legal option for human use through US compounding.
How It Works (Mechanism of Action)
MOTS-c is encoded in the mitochondrial genome and appears to influence metabolism and possibly exercise capacity and insulin sensitivity in animal models. Human mechanisms are not well established.
Primary Uses
Marketed uses include metabolic regulation and insulin sensitivity. Evidence is emerging—primarily animal studies. Not legally available for human use in the US.
FDA & Regulatory Status
Prohibited for compounding. Category 2 / no pathway to compound. Not FDA-approved.
Last reviewed February 2026.
Clinical Evidence
Emerging—primarily animal studies.
Side Effects & Safety
Limited human data. Not legally available in the US.
What to Expect at a Clinic
US clinics should not offer MOTS-c for human use. For metabolic support, consider FDA-approved GLP-1 therapies or other legal options.
